Bringing unmatched commerical experience and world-renowned science to the vital field of protein modulation.

BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven commercial success to deliver efficacious therapies to patients with unmet medical needs. The team’s core expertise is to discover and develop molecules that regulate protein homeostasis and stimulate the immune system to destroy cancers with minimal toxicities by utilizing enhanced biology-driven models. As a result, these novel drug candidates have large therapeutic windows. When coupled with clinically proven translational therapeutics targeting cancer and immune dysregulation, our goal is a rapid delivery of new drugs to improve lives of patients in need.


May 4, 2016 - Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers

Get in touch